{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Griesinger AM"],"funding":["National Center for Advancing Translational Sciences","NCATS NIH HHS","Tanner Seebaum Foundation","U.S. Department of Defense","National Cancer Institute","NCI NIH HHS","NIH HHS","Office of Research Infrastructure Programs"],"pagination":["1544-1554"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11018467"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(8)"],"pubmed_abstract":["<h4>Purpose</h4>There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA tumors, and this number doubles at recurrence. Seventy percent of children with chromosome 1q+ PFA will die because of the tumor, highlighting the urgent need to develop new therapeutic strategies for this population.<h4>Experimental design</h4>In this study, we utilize 1q+ PFA in vitro and in vivo models to test the efficacy of combination radiation and chemotherapy in a preclinical setting.<h4>Results</h4>5-fluorouracil (5FU) enhances radiotherapy in 1q+ PFA cell lines. Specifically, 5FU increases p53 activity mediated by the extra copy of UCK2 located on chromosome 1q in 1q+ "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma."],"pmcid":["PMC11018467"],"funding_grant_id":["P30 CA046934","P30CA046934","S10 OD023485","S10OD023485","UM1 TR004399","CA190494"],"pubmed_authors":["Dorris K","Serkova NJ","Grimaldo E","Griesinger AM","Calzadilla AJ","Wright KD","Handler M","Donson AM","Bertrand KC","Vibhakar R","Steiner J","Amani V","Pierce AM","Kargar S","Lindsay HB","Foreman NK","Hankinson T"],"additional_accession":[]},"is_claimable":false,"name":"Development of Chromosome 1q+ Specific Treatment for Highest Risk Pediatric Posterior Fossa Ependymoma.","description":"<h4>Purpose</h4>There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) are present in approximately 25% of newly diagnosed PFA tumors, and this number doubles at recurrence. Seventy percent of children with chromosome 1q+ PFA will die because of the tumor, highlighting the urgent need to develop new therapeutic strategies for this population.<h4>Experimental design</h4>In this study, we utilize 1q+ PFA in vitro and in vivo models to test the efficacy of combination radiation and chemotherapy in a preclinical setting.<h4>Results</h4>5-fluorouracil (5FU) enhances radiotherapy in 1q+ PFA cell lines. Specifically, 5FU increases p53 activity mediated by the extra copy of UCK2 located on chromosome 1q in 1q+ ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T07:06:23.481Z","creation":"2025-04-04T23:50:09.553Z"},"accession":"S-EPMC11018467","cross_references":{"pubmed":["38334950"],"doi":["10.1158/1078-0432.ccr-23-3156","10.1158/1078-0432.CCR-23-3156"]}}